Measurable residual disease in the treatment of chronic lymphocytic leukemia
| Autor: | Takayoshi Uchiyama, Aki Yokoyama, Sadao Aoki |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty measurable residual disease Neoplasm Residual medicine.medical_treatment Chronic lymphocytic leukemia Context (language use) Disease Review Article Real-Time Polymerase Chain Reaction 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chemoimmunotherapy immune system diseases ibrutinib Internal medicine hemic and lymphatic diseases medicine Humans multicolor flow cytometry Chemotherapy Sulfonamides venetoclax business.industry Venetoclax High-Throughput Nucleotide Sequencing General Medicine medicine.disease Bridged Bicyclo Compounds Heterocyclic Flow Cytometry Leukemia Lymphocytic Chronic B-Cell Clinical trial body regions chemistry 030220 oncology & carcinogenesis Ibrutinib chronic lymphocytic leukemia business 030215 immunology |
| Zdroj: | Journal of Clinical and Experimental Hematopathology : JCEH |
| ISSN: | 1880-9952 1346-4280 |
| Popis: | Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in several clinical trials on CLL using flow cytometry, real-time quantitative PCR (RQ-PCR) with allele-specific oligonucleotide (ASO) primers, and high-throughput sequencing. MRD assessment is useful to predict the treatment outcomes in the context of chemotherapy and treatment with novel drugs such as venetoclax. In this review, we discuss major techniques for MRD assessment, data from relevant clinical trials, and the future of MRD assessment in CLL treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|